Lam Research Revenue Jumps 27.7%, Net Income Soars 40.5%

TL;DR

**LRCX is crushing it, riding the wave of strong chip demand and expanding its lead in critical markets.**

AI Summary

Lam Research Corporation reported a robust financial performance for the three months ended September 28, 2025, with revenue increasing by 27.7% to $5.32 billion from $4.17 billion in the prior year. Net income surged by 40.5% to $1.57 billion, up from $1.12 billion in the same period last year. This growth was primarily driven by a significant 48.2% increase in Systems revenue, reaching $3.55 billion compared to $2.39 billion. Geographically, China was a major contributor, with revenue from the region growing by 46.5% to $2.28 billion. The company's gross margin improved to 50.4% from 48.1% year-over-year. Operating income also saw a substantial rise of 44.7% to $1.83 billion. Diluted net income per share increased to $1.24 from $0.86. The company's cash and cash equivalents grew to $6.69 billion from $6.39 billion at the end of the previous quarter, reflecting strong cash generation from operating activities of $1.78 billion. Strategic outlook remains positive, with continued investment in R&D, which increased to $576.4 million from $495.4 million.

Why It Matters

This strong performance from Lam Research signals robust demand in the semiconductor equipment sector, particularly for leading-edge wafer fabrication. For investors, the significant revenue and net income growth, coupled with increased cash flow, suggests strong operational efficiency and market leadership, potentially driving stock appreciation. Employees benefit from a thriving company, while customers gain access to advanced technology crucial for their own innovation. In a competitive landscape, Lam Research's ability to capture substantial market share, especially in China and Taiwan, reinforces its position against rivals like Applied Materials and Tokyo Electron, indicating a healthy and expanding market for chip manufacturing tools.

Risk Assessment

Risk Level: medium — While financial performance is strong, the company's significant revenue concentration in China ($2.28 billion, or 42.9% of total revenue) presents a geopolitical risk. Additionally, the increase in income tax expense to $290.5 million from $177.8 million, and the mention of new tax legislation (OBBBA) and BEPS 2.0, indicate potential future tax volatility, even if the immediate impact was deemed 'not material'.

Analyst Insight

Investors should consider Lam Research a strong buy, given its impressive revenue and net income growth, particularly in the critical Systems segment. Monitor geopolitical developments concerning China and potential impacts on trade policies, as this represents a notable concentration risk. The company's consistent R&D investment and strong cash flow position it well for continued innovation and market leadership.

Financial Highlights

revenue

$5.32B

operating Margin

34.3%

total Assets

$21.90B

total Debt

$4.48B

net Income

$1.57B

eps

$1.24

gross Margin

50.4%

cash Position

$6.69B

revenue Growth

+27.7%

Revenue Breakdown

Key Numbers

• $5.32B — Revenue (Increased 27.7% from $4.17 billion year-over-year)
• $1.57B — Net Income (Increased 40.5% from $1.12 billion year-over-year)
• $1.24 — Diluted Net Income Per Share (Increased from $0.86 year-over-year)
• $3.55B — Systems Revenue (Increased 48.2% from $2.39 billion year-over-year)
• $2.28B — Revenue from China (Increased 46.5% from $1.56 billion year-over-year)
• 50.4% — Gross Margin (Improved from 48.1% year-over-year)
• $1.83B — Operating Income (Increased 44.7% from $1.26 billion year-over-year)
• $6.69B — Cash and Cash Equivalents (Increased from $6.39 billion quarter-over-quarter)
• $1.78B — Net Cash Provided by Operating Activities (Increased from $1.57 billion year-over-year)
• $576.4M — Research and Development Expense (Increased from $495.4 million year-over-year)

Key Players & Entities

• LAM RESEARCH CORP (company) — registrant
• Donald Trump (person) — U.S. President who signed OBBBA
• Internal Revenue Service (regulator) — examining tax returns
• FASB (regulator) — issued accounting standards
• China (company) — geographic region with $2.28 billion revenue
• Taiwan (company) — geographic region with $1.03 billion revenue
• Nasdaq Stock Market (company) — exchange where common stock is registered
• One Big Beautiful Bill Act (regulator) — new U.S. tax legislation
• Bloomberg (company) — publisher of this analysis
• Applied Materials (company) — competitor

FAQ

Risk Factors

• Semiconductor Industry Cyclicality [high — market]: The semiconductor industry is inherently cyclical, subject to fluctuations in supply and demand. A downturn in chip demand or oversupply could negatively impact Lam Research's revenue and profitability, as seen in historical industry cycles.
• Geopolitical and Trade Restrictions [high — regulatory]: Increasing geopolitical tensions and trade restrictions, particularly concerning exports to China, pose a significant risk. These restrictions can limit market access and disrupt supply chains, impacting revenue from key regions like China, which grew 46.5% to $2.28 billion in the quarter.
• Supply Chain Disruptions [medium — operational]: Reliance on a global supply chain for components makes Lam Research vulnerable to disruptions from natural disasters, pandemics, or geopolitical events. Such disruptions could affect production capacity and timely delivery of products, impacting revenue and customer relationships.
• Foreign Currency Exchange Rate Fluctuations [medium — financial]: As a global company, Lam Research is exposed to foreign currency exchange rate fluctuations. Adverse movements in exchange rates can impact the reported value of international revenues and expenses, affecting net income. The company reported a foreign currency translation adjustment of ($12.7) million for the three months ended September 28, 2025.
• Intense Competition [medium — market]: The semiconductor equipment market is highly competitive, with several large players vying for market share. Continuous innovation and significant R&D investment, which increased to $576.4 million from $495.4 million, are necessary to maintain a competitive edge.

Industry Context

Lam Research operates in the highly dynamic semiconductor equipment manufacturing industry, which is critical for enabling advancements in computing, AI, and mobile technologies. The sector is characterized by intense competition, rapid technological evolution, and significant capital expenditure by chip manufacturers. Key trends include the increasing complexity of chip designs, the demand for advanced memory and logic devices, and the ongoing geopolitical shifts influencing global supply chains.

Regulatory Implications

The company faces regulatory scrutiny related to international trade policies, particularly concerning exports to China. Compliance with export controls and sanctions is crucial, as violations can lead to severe penalties and operational disruptions. Additionally, environmental regulations and labor laws in various operating jurisdictions require ongoing adherence.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]

Key Dates

• 2025-09-28: End of Q3 2025 Fiscal Period — Reporting period for the strong financial results, showing significant revenue and net income growth.
• 2025-06-29: End of Q2 2025 Fiscal Period — Previous quarter-end, used for comparison of cash and cash equivalents, which increased from $6.39 billion.
• 2024-09-29: End of Q3 2024 Fiscal Period — Prior year comparable period, used for year-over-year growth calculations in revenue, net income, and margins.

Glossary

Gross Margin

The difference between revenue and the cost of goods sold, expressed as a percentage of revenue. It indicates the profitability of a company's core operations before accounting for operating expenses. (Improved to 50.4% from 48.1%, demonstrating increased efficiency in production or pricing power.)

Operating Income

Profitability from a company's core business operations, calculated as revenue minus cost of goods sold and operating expenses (R&D, SG&A). (Increased by 44.7% to $1.83 billion, reflecting strong operational performance and cost management.)

Diluted Net Income Per Share

Net income divided by the total number of outstanding shares, including the effect of all dilutive potential common shares (like stock options and convertible securities). (Increased to $1.24 from $0.86, showing improved profitability on a per-share basis for shareholders.)

Cash and Cash Equivalents

Short-term, highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. (Grew to $6.69 billion from $6.39 billion, indicating strong cash generation and a healthy liquidity position.)

Net Cash Provided by Operating Activities

The net amount of cash generated from a company's normal business operations over a period. (Reported at $1.78 billion, this robust figure highlights the company's ability to generate cash from its core business, supporting growth and investments.)

Research and Development Expense

Costs incurred by a company to develop new products or services, or to improve existing ones. (Increased to $576.4 million from $495.4 million, signaling continued investment in innovation to maintain market leadership.)

Year-Over-Year Comparison

Compared to the prior year's comparable period, Lam Research has demonstrated substantial growth. Revenue surged by 27.7% to $5.32 billion, driven by a remarkable 48.2% increase in Systems revenue. Net income saw a significant uplift of 40.5% to $1.57 billion, with diluted EPS rising to $1.24 from $0.86. The gross margin improved to 50.4% from 48.1%, indicating enhanced operational efficiency or pricing power. No new material risks were explicitly highlighted in the provided excerpt, but the existing risks related to geopolitical factors and industry cyclicality remain pertinent.

Key Financial Figures

• $0.001 — ich registered Common Stock, Par Value $0.001 Per Share LRCX The Nasdaq Stock Market

Filing Documents

• lrcx-20250928.htm (10-Q) — 835KB
• lam_edcpxiixfinalxapproved.htm (EX-10.1) — 176KB
• lrcx_1qx2026xexhibitx311.htm (EX-31.1) — 7KB
• lrcx_1qx2026xexhibitx312.htm (EX-31.2) — 8KB
• lrcx_1qx2026xexhibitx321.htm (EX-32.1) — 4KB
• lrcx_1qx2026xexhibitx322.htm (EX-32.2) — 4KB
• 0000707549-25-000085.txt ( ) — 4519KB
• lrcx-20250928.xsd (EX-101.SCH) — 32KB
• lrcx-20250928_cal.xml (EX-101.CAL) — 53KB
• lrcx-20250928_def.xml (EX-101.DEF) — 75KB
• lrcx-20250928_lab.xml (EX-101.LAB) — 418KB
• lrcx-20250928_pre.xml (EX-101.PRE) — 271KB
• lrcx-20250928_htm.xml (XML) — 460KB

Financial Information

PART I. Financial Information

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited): Condensed Consolidated Statements of Operations for the three months ended September 28, 2025, and September 29, 2024 3 Condensed Consolidated Statements of Comprehensive Income for the three months ended September 28, 2025, and September 29, 2024 4 Condensed Consolidated Balance Sheets as of September 28, 2025, and June 29, 2025 5 Condensed Consolidated Statements of Cash Flows for the three months ended September 28, 2025, and September 29, 2024 6 Condensed Consolidated Statements of Stockholders' Equity for the three months ended September 28, 2025, and September 29, 2024 7 Notes to Condensed Consolidated Financial Statements 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 16

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 22

Controls and Procedures

Item 4. Controls and Procedures 23

Other Information

PART II. Other Information

Legal Proceedings

Item 1. Legal Proceedings 24

Risk Factors

Item 1A. Risk Factors 24

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 37

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 37

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 37

Other Information

Item 5. Other Information 37

Exhibits

Item 6. Exhibits 38

Signatures

Signatures 39 Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

ITEM 1. Financial Statements LAM RESEARCH CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data) (unaudited) Three Months Ended September 28, 2025 September 29, 2024 Revenue $ 5,324,173 $ 4,167,976 Cost of goods sold 2,639,294 2,165,293 Gross margin 2,684,879 2,002,683 Research and development 576,446 495,358 Selling, general, and administrative 279,345 243,128 Total operating expenses 855,791 738,486 Operating income 1,829,088 1,264,197 Other income (expense), net 30,074 30,081 Income before income taxes 1,859,162 1,294,278 Income tax expense ( 290,502 ) ( 177,834 ) Net income $ 1,568,660 $ 1,116,444 Net income per share: Basic $ 1.24 $ 0.86 Diluted $ 1.24 $ 0.86 Number of shares used in per share calculations: Basic 1,264,446 1,299,236 Diluted 1,269,313 1,304,066 See Notes to Condensed Consolidated Financial Statements Lam Research Corporation 2025 Q3 10-Q 3 Table of Contents LAM RESEARCH CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (in thousands) (unaudited) Three Months Ended September 28, 2025 September 29, 2024 Net income $ 1,568,660 $ 1,116,444 Other comprehensive income (loss), net of tax: Foreign currency translation adjustment ( 12,726 ) 45,126 Cash flow hedges: Net unrealized gains (losses) during the period 8,570 ( 2,436 ) Net gains reclassified into net income ( 7,095 ) ( 104 ) 1,475 ( 2,540 ) Defined benefit plans, net change in unrealized component 83 39 Other comprehensive income (loss), net of tax ( 11,168 ) 42,625 Comprehensive income $ 1,557,492 $ 1,159,069 See Notes to Condensed Consolidated Financial Statements Lam Research Corporation 2025 Q3 10-Q 4 Table of Contents LAM RESEARCH CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except per share data) September 28, 2025 June 29, 2025 (unaudited) (1) ASSETS Cash and cash equivalents $ 6,693,046 $ 6,390,659 Accounts receivable, less allowance of $